BBIO · Healthcare
Bridgebio Pharma Inc
26/100
Smart-money confidence1 of 3 sources positive
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
34
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$16.4B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About BRIDGEBIO PHARMA INC
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3…
Who's behind the signal
Every informed buyer we can see on BBIO, across all three feeds.
Hedge funds · 6
Citadel Advisors
Increased +355%
D.E. Shaw & Co
Increased +15%
Bridgewater Associates (Dalio)
Increased +501%
Millennium Management (Englander)
Increased +1631%
AQR Capital Management
Increased +19%
Viking Global Investors
Decreased −18%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
BRIDGEBIO PHARMA INC isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
0
New positions
5
Increasing
1
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.2%
Position change
+355%
0.2% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.2%
Position change
+15%
0.2% of D.E. Shaw & Co's portfolio
Trust weight: 1.3×
% of portfolio
0.1%
Position change
+501%
0.1% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+1631%
0.0% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+19%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.5×
% of portfolio
2.5%
Position change
−18%
2.5% of Viking Global Investors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to BRIDGEBIO PHARMA INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell BRIDGEBIO PHARMA INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订